Amin Alousi, MD
Internal Medicine · Houston, TXNPI 1023118015
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $76,860 of the $126,622 with a category attached, or 60.7%. It is spread thinly across 19 manufacturers, the largest accounting for just 20.9%. 2025 is the largest year on record at $42,578, 2.9 times the $14,706 reported in 2019. Among internal medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 95 payments — averaging $1332.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$27K
- Incyte Corporation$17K
- Sanofi-aventis U.S. LLC$17K
- Therakos LLC$14K
- Mallinckrodt Hospital Products Inc.$11K
- Genentech, Inc.$10K
- plus $31K from 13 others
Across 197 payments — averaging $16,411 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$2.2M
- National Marrow Donor Program$573K
- Incyte Corporation$313K
- Syndax Pharmaceuticals, Inc.$95K
- Sanofi US Services Inc.$46K
- Sanofi-aventis U.S. LLC$1K
- plus $1 from 1 others
What the payments were for
- Consulting fees$76,86061%
- Speaking & faculty fees$25,10520%
- Travel & lodging$20,28416%
- Food & beverage$4,3723%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 20 | $26,512 |
| Incyte Corporation | 19 | $16,605 |
| Sanofi-aventis U.S. LLC | 11 | $16,532 |
| Therakos LLC | 2 | $14,305 |
| Mallinckrodt Hospital Products Inc. | 3 | $10,985 |
| Genentech, Inc. | 3 | $10,426 |
| Kadmon Pharmaceuticals LLC | 7 | $7,147 |
| Sanofi US Services Inc. | 1 | $5,817 |
| National Marrow Donor Program | 13 | $4,461 |
| AstraZeneca | 2 | $3,750 |
| Sanofi | 2 | $3,594 |
| Deciphera Pharmaceuticals Inc. | 1 | $2,475 |
| Aimmune Therapeutics, Inc. | 1 | $1,925 |
| Genentech USA, Inc. | 4 | $1,433 |
| Jazz Pharmaceuticals Inc. | 2 | $278 |
| Kadmon Corporation LLC | 1 | $144 |
| Rigel Pharmaceuticals, Inc. | 1 | $116 |
| Stemline Therapeutics Inc. | 1 | $102 |
| Bristol Myers Squibb | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$126,622 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrevymisLetermovir | 19 | $130,397 |
| VenclextaVenetoclax | 19 | $14,757 |
| Posaconazole | 12 | $12,713 |
| Atovaquone | 16 | $8,354 |
| ValacyclovirValacyclovir Hcl | 29 | $1,297 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Houston
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
- Krina PatelHouston$255K
- Nicholas ShortHouston$247K
- Naveen PemmarajuHouston$230K
- Mariana Chavez MacgregorHouston$188K
- Shumei KatoHouston$180K
- Sukhdeep BasraHouston$168K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.